Sensitivity of ultrasound in detecting hepatocellular carcinoma in obese patients compared to explant pathology as the gold standard
0
조회
0
다운로드
6
인용
0
참고문헌
키워드
초록
Background/Aims: The American Association for the Study of Liver Diseases recommends ultrasound (US) screening for hepatocellular carcinoma (HCC) among cirrhotic patients, regardless of body mass index (BMI), every 6 months. We examined US sensitivity for diagnosis of HCC in obese patients. Methods: Liver transplant patients data with HCC in explant was used (January 2012-December 2017). All patients underwent liver US within 3 months of diagnosis of HCC. Number/size of HCC lesions were extracted from radiologic and pathologic reports. Obesity was defined as BMI ≥30 kg/m2. Results: One hundred sixteen patients were included. 80% were male, with mean BMI of 31 kg/m2. The most common underlying liver disease was hepatitis C virus (62%). At the time of diagnosis, median number of HCC lesions was 2 (interquartile range [IQR], 1–3), and median size of the largest lesion was 2.5 cm (IQR, 1.75–3.9). Overall sensitivity of US study for detection of HCC was 33% (95% confidence interval [CI], 29–48%). Sensitivity was 77% (95% CI, 62–93%) in patients with BMI<30 and 21% (95% CI, 11–30%) in patients with BMI≥30 (P<0.001). Size of the largest HCC lesion (P=0.290) and number of lesions (P=0.505) were not different between groups. Computed tomography (CT) scan detected HCC in 98% of the obese patients with negative US. Conclusions: Sensitivity of US for detection of HCC is significantly lower among obese patients compared to overweight and normal weight patients. These patients may benefit from alternating between US and a different imaging modality.
Abstract
Background/Aims: The American Association for the Study of Liver Diseases recommends ultrasound (US) screening for hepatocellular carcinoma (HCC) among cirrhotic patients, regardless of body mass index (BMI), every 6 months. We examined US sensitivity for diagnosis of HCC in obese patients. Methods: Liver transplant patients data with HCC in explant was used (January 2012-December 2017). All patients underwent liver US within 3 months of diagnosis of HCC. Number/size of HCC lesions were extracted from radiologic and pathologic reports. Obesity was defined as BMI ≥30 kg/m2. Results: One hundred sixteen patients were included. 80% were male, with mean BMI of 31 kg/m2. The most common underlying liver disease was hepatitis C virus (62%). At the time of diagnosis, median number of HCC lesions was 2 (interquartile range [IQR], 1–3), and median size of the largest lesion was 2.5 cm (IQR, 1.75–3.9). Overall sensitivity of US study for detection of HCC was 33% (95% confidence interval [CI], 29–48%). Sensitivity was 77% (95% CI, 62–93%) in patients with BMI<30 and 21% (95% CI, 11–30%) in patients with BMI≥30 (P<0.001). Size of the largest HCC lesion (P=0.290) and number of lesions (P=0.505) were not different between groups. Computed tomography (CT) scan detected HCC in 98% of the obese patients with negative US. Conclusions: Sensitivity of US for detection of HCC is significantly lower among obese patients compared to overweight and normal weight patients. These patients may benefit from alternating between US and a different imaging modality.
참고문헌 (28)
- Global Burden of Disease Liver Cancer Collaboration, "The burden of primary liver cancer and underlying etiologies from 1990 to 2015at the global, regional, and national level : results from the global burden of disease study 2015", JAMA Oncol, 3, pp.1683~1691 (2017)
- Bruix J, "Management of hepatocellular carcinoma: an update", Hepatology, 53, pp.1020~1022 (2011)
- European Association For The Study Of The Liver, "EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma", J Hepatol, 56, pp.908~943 (2012)
- Ryder SD, "Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults", Gut, 52(Suppl 3), pp.iii1~iii8 (2003)
- Bruix J, "American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma", Hepatology, 42, pp.1208~1236 (2005)
- Singal A, "Meta-analysis : surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis", Aliment Pharmacol Ther, 30, pp.37~47 (2009)
- Lok AS, "Des-gamma-carboxy prothrombin and alpha-fetoprotein as biomarkers for the early detection of hepatocellular carcinoma", Gastroenterology, 138, pp.493~502 (2010)
- Forner A, "Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis : prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma", Hepatology, 47, pp.97~104 (2008)
- Sangiovanni A, "The diagnostic and economic impact of contrast imaging techniques in the diagnosis of small hepatocellular carcinoma in cirrhosis", Gut, 59, pp.638~644 (2010)
- Mikami S, "Tumor markers are more useful in patients undergoing surveillance for hepatocellular carcinoma with unreliable results by ultrasonography", Hepatol Res, 45, pp.415~422 (2015)
- Sato T, "Ultrasound surveillance for early detection of hepatocellular carcinoma among patients with chronic hepatitis C", Hepatol Int, 3, pp.544~550 (2009)
- Stevens GA, "National, regional, and global trends in adult overweight and obesity prevalences", Popul Health Metr, 10, pp.22~ (2012)
- Marchesini G, "Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome", Hepatology, 37, pp.917~923 (2003)
- Wanless IR, "Fatty liver hepatitis(steatohepatitis)and obesity : an autopsy study with analysis of risk factors", Hepatology, 12, pp.1106~1110 (1990)
- Rinella ME, "Nonalcoholic fatty liver disease : a systematic review", JAMA, 313, pp.2263~2273 (2015)
- Younossi ZM, "Association of nonalcoholic fatty liver disease(NAFLD)with hepatocellular carcinoma(HCC)in the United States from 2004 to 2009", Hepatology, 62, pp.1723~1730 (2015)
- Hashimoto E, "Hepatocellular carcinoma in non-alcoholic steatohepatitis : growing evidence of an epidemic?", Hepatol Res, 42, pp.1~14 (2012)
- Bugianesi E, "Expanding the natural history of nonalcoholic steatohepatitis : from cryptogenic cirrhosis to hepatocellular carcinoma", Gastroenterology, 123, pp.134~140 (2002)
- Hashimoto E, "Hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", J Gastroenterol 2009;44 Suppl, 44(Suppl 19), pp.89~95 (2009)
- Ascha MS, "The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis", Hepatology, 51, pp.1972~1978 (2010)
- Yasui K, "Characteristics of patients with nonalcoholic steatohepatitis who develop hepatocellular carcinoma", Clin Gastroenterol Hepatol, 9, pp.428~433 (2011)
- Mittal S, "hepatocellular carcinoma in the absence of cirrhosis in United States veterans is associated with nonalcoholic fatty liver disease", Clin Gastroenterol Hepatol, 14, pp.124~131.e1 (2016)
- Heimbach JK, "AASLD guidelines for the treatment of hepatocellular carcinoma", Hepatology, 67, pp.358~380 (2018)
- Yu NC, "CT and MRI improve detection of hepatocellular carcinoma, compared with ultrasound alone, in patients with cirrhosis", Clin Gastroenterol Hepatol, 9, pp.161~167 (2011)
- Kolly P, "Surveillance for hepatocellular carcinoma in patients with NASH", Diagnostics(Basel), 6, pp.22~ (2016)
- Hales CM, "Prevalence of obesity among adults and youth : United States, 2015-2016", NCHS Data Brief, (288), pp.1~8 (2017)
- Mazzaferro V, "Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis", N Engl J Med, 334, pp.693~699 (1996)
- Chalasani N, "Screening for hepatocellular carcinoma in patients with cirrhosis in the United States : results of a national survey", Am J Gastroenterol, 94, pp.2224~2229 (1999)